Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LEAP-011: pembrolizumab + lenvatinib versus pembrolizumab + placebo in first-line platinum-ineligible advanced urothelial carcinoma
jRCT2080224732Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jun 2019
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in transitional cell carcinoma (TCC) comparing Pembrolizumab + lenvatinib with Pembrolizumab + placebo (2 arms). Primary endpoints: Overall survival, Progression-free survival and 1 more. Started Jun 2019; status: completed.
02
Drugs
pembrolizumablenvatinib
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on jRCT2080224732.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224732.